ORMP News Alert Oramed Pharmaceuticl (ORMP) 5.41 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oramed Pharmaceuticl (ORMP) 5.41 $ORMP

Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 16, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
LNCO: 10.87 (+1.71), ORMP: 5.41 (-0.47), INFI: 16.13 (+0.55), LINE: 12.54 (+2.71), ORPN: 6.54 (-0.07), JAXB: 11.25 (-0.99), CLMT: 21.54 (+1.78), OBAS: 6.96 (-0.06)

Oramed snags $5M investment from Chinese pharma
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:04AM CST

ORMP: 5.41 (-0.47)

Oramed Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company
PR Newswire - Wed Dec 03, 7:25AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:600252) previously reported on November 3, 2014, for the purchase of 696,378 restricted shares of common stock for $7.18 per share, the closing price of Oramed's common stock on Friday, October 31, 2014, in a private placement.
ORMP: 5.41 (-0.47)

Oramed Pharmaceuticals at LD MICRO "Main Event" Micro-Cap Growth Conference on December 2, 2014
PR Newswire - Mon Dec 01, 7:15AM CST
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Company management will participate in the upcoming LD MICRO "Main Event" Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Michael Berelowitz, M.D., Director and Chairman of the Scientific Advisory Board of Oramed, will present a corporate overview on Tuesday, December 2, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
ORMP: 5.41 (-0.47)

Coverage Initiation Report Focuses on Oramed Pharmaceuticals
Marketwired - Tue Nov 11, 7:45AM CST
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is the subject of a new in-depth initiation coverage repot by Acceleron Equity Research.
ORMP: 5.41 (-0.47)

Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Fri Oct 31, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)(http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes on Monday, November 3, 2014 at 10:00 a.m. Eastern time.
ORMP: 5.41 (-0.47)

Oramed to Present at the FireRock Annual Micro-Cap Conference
PR Newswire - Fri Oct 24, 7:25AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company's CEO, Nadav Kidron will present at FireRock Capital's Micro-Cap Conference.
ORMP: 5.41 (-0.47)

Oramed Pharmaceuticals announces positive top-line clinical results from Phase IIa clinical trial of ORMD-0801 for treatment of type 1 diabetes
M2 - Wed Oct 22, 10:39AM CDT
Oramed Pharmaceuticals Inc (NASDAQCM: ORMP), a clinical-stage pharmaceutical company that developms oral drug delivery systems, announce on Wednesday that its Phase IIa clinical trial of ORMD-0801, its proprietary oral insulin capsules to treat type 1 diabetes, has achieved positive top-line clinical results.
ORMP: 5.41 (-0.47)

Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
PR Newswire - Wed Oct 22, 7:29AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. The trial was conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
ORMP: 5.41 (-0.47)

Oramed to Present at Family Office & Wealth Management Conference
PR Newswire - Mon Sep 15, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at DC Finance's Family Office & Wealth Management Annual Conference.
ORMP: 5.41 (-0.47)

Oramed's Insulin Pill Superior to New Diabetes Drugs Gaining Approval
ACCESSWIRE - Thu Sep 11, 7:01AM CDT
Los Angeles, CA / September 11, 2014 / Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (LLY:NYSE) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an onerous side effect profile that rivals medications like Bristol-Myers Squibb's (BMY:NYSE) anti-blood clot drug Plavix which has caused internal bleeding that results in vomiting coagulated blood. Medicine for diabetics, one of the largest populations of sick patients in the US, should look to more natural means for bringing insulin into the body. Oramed Pharmaceuticals, Inc. (ORMP:NASDAQ) offers a potential remedy and has been making good progress in clinical trials, as outlined below.
ORMP: 5.41 (-0.47), LLY: 69.26 (-0.41), BMY: 57.69 (-0.86)

Oramed to Present at Upcoming Conferences
PR Newswire - Wed Sep 03, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the Company's CEO, Nadav Kidron will present at the following conferences in September 2014:
ORMP: 5.41 (-0.47)

Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014
M2 - Tue Aug 19, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4zkt/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering. The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity. In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market. The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market. The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage - Additional comments with a hyperlink leading to the source of information. Key Topics Covered: 1. Selective GLP-1 Analogs for Metabolic Diseases - 2013 Sales of GLP-1 Analogs - Short-Acting Injectable GLP-1 Analogs - Long-Acting Injectable GLP-1 Analogs - Very Long-Acting Injectable GLP-1 Analogs - Oral Peptide-Based GLP-1 Analogs - Other Non-Injectable Peptide-Based GLP-1 Analogs - Oral Small Molecule GLP-1 Receptor Agonists 2. Selective GLP-1 Analogs for Non-Metabolic Diseases 3. Dual Target GLP-1 Analogs - GLP-1 and Insulin - GLP-1 and Glucagon - GLP-1 and GIP - GLP-1 and Gastrin/CCKB - GLP-1 and GLP-2 4. Corporate GLP-1 Receptor Agonist R&D Pipelines Companies Mentioned - Addex Pharmaceuticals - Amylin Pharmaceuticals - Arisaph Pharmaceuticals - Arisgen - Ascendis Pharma (Complex Biosystems) - Bio-ker - Biocompatibles International - ConjuChem - Dong-A Pharmaceutical - Eli Lilly - Emisphere Technologies - Faust Pharmaceuticals - GlaxoSmithKline - Hanmi Pharmaceuticals - Ipse - Mannkind - MDRNA (ex Nastech Pharmaceuticals) - Modigene - Novo Nordisk - OctoPlus - Oramed Pharmaceuticals - Pfizer - Proxima Concepts - Roche (& Chugai) - Rose Pharmaceuticals (ex Gastrotech) - Sanofi-Aventis - Teijin - Transition Therapeutics - TransTech Pharma - Unigene For more information visit http://www.researchandmarkets.com/research/7d4zkt/competitor
NVO: 43.29 (-0.35), ORMP: 5.41 (-0.47), TTHI: 6.45 (unch), LLY: 69.26 (-0.41), GSK: 41.92 (+0.62)

Oramed Granted Patent in Spain for Oral Administration of Insulin
PR Newswire - Tue Aug 19, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Spain has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
ORMP: 5.41 (-0.47)

Oramed Pharmaceuticals treats last patient with ORMD-0801 in Phase IIa trial for type 1 diabetes
M2 - Fri Aug 08, 5:57AM CDT
Pharmaceutical company Oramed Pharmaceuticals (NasdaqCM:ORMP) reported on Thursday the treatment of the last type 1 diabetes patient under its Phase IIa clinical trial of ORMD-0801.
ORMP: 5.41 (-0.47)

Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
PR Newswire - Thu Aug 07, 7:20AM CDT
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today reports that the last patient has completed treatment in its Phase IIa clinical trial of ORMD-0801, the Company's proprietary oral insulin capsule, to treat type 1 diabetes, and top-line data is expected to be reported in the fourth quarter of 2014. The trial was conducted in the United States under a Food and Drug Administration Investigational New Drug protocol.
ORMP: 5.41 (-0.47)

Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego
PR Newswire - Mon Jun 23, 7:15AM CDT
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chief Executive Officer, Nadav Kidron, will present at the 2014 BIO International Convention. This year's global event for biotechnology will take place on June 23-26 at the San Diego Convention Center in San Diego, California.
ORMP: 5.41 (-0.47)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 73

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 99

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 86

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 90

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
OFRM Recall Leaves Investors Facing Hard Questions

Updated Category News Views 22

Nothing wrecks a young consumer brand’s glow faster than a recall involving toddlers, and Once Upon A Farm has just learned that lesson in the ugliest possible way. On November 2, 2026, shares of NYSE:OFRM fell 37% to close at $9.44. That left the stock roughly 47% below its $18 IPO price. Those are not the garden-variety bruises of a weak quarter. That is the market...

Continue Reading
Century Lithium Clears a Crucial Nevada Permit Gate

Updated Category News Views 24

Permitting news rarely rings a cash register, but it can stop one from being bolted shut. Century Lithium has received confirmation from the Bureau of Land Management’s Tonopah Field Office that baseline studies for its wholly owned Angel Island lithium project in Esmeralda County, Nevada, are complete. The agency also set the project on the Environmental Impact...

Continue Reading
GFT's Banking Leader Tag Puts Execution Risks Into Focus

Updated Category News Views 82

A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 95

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading

Top 5 Most Recently Viewed Articles

Insights from the Global MOOC Conference on Future Education Trends

Updated Category News Views 197

The 2025 Global MOOC and Online Education Conference Overview The 2025 Global MOOC and Online Education Conference took place at the National Autonomous University of Mexico (UNAM) and focused on the theme of breaking boundaries to reshape futures in education. This event gathered educators and leaders in the field to discuss the future of online learning, with a...

Continue Reading
Truist Securities Predicts Growth Surge for Amazon Stock

Updated Category News Views 105

Amazon.com Inc (NASDAQ: AMZN) caught the attention of traders when Truist Securities boosted its price target from $230 to $265 back in early 2024. This wasn’t just a haphazard bump; they backed it with analysis that showed Amazon’s North American revenue holding steady, proving that consumers still love their Prime subscriptions and shopping sprees. What's fueling...

Continue Reading
Exploring the Rise of Probiotics in Animal Nutrition Market

Updated Category News Views 217

Understanding the Growth of Probiotics in Animal Feed As the demand for sustainable and antibiotic-free farming practices increases, the global probiotics in animal feed market is experiencing remarkable growth. Recent projections indicate that this market is expected to rise significantly, reflecting a shift in agricultural practices aimed at enhancing animal health and...

Continue Reading
Ascidian Therapeutics Announces Key Appointment to Advance Eyecare

Updated Category News Views 324

Key Appointment and New Advisory Board at Ascidian Therapeutics Ascidian Therapeutics, a pioneering biotechnology company focused on rewriting RNA to combat human diseases, has made a significant announcement. They have appointed Dr. Murray A. Abramson as Chief Development Officer (CDO) and created an Ophthalmology Clinical Advisory Board. This strategic move aims to...

Continue Reading
Waymo's Latest Robotaxi Innovation Marks a New Self-Driving Era

Updated Category News Views 375

Waymo's New Robotaxi Launches with Advanced Self-Driving Features Alphabet Inc.'s autonomous ride-hailing company, Waymo, has taken a significant step by introducing its latest Robotaxi equipped with sixth-generation self-driving technology. This advanced vehicle is now undergoing rigorous testing to ensure its readiness for the ever-competitive self-driving market....

Continue Reading